The Global Market for Pain Management Drugs and Devices

360 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
360
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

The Global Market for Pain Management Drugs and Devices

  1. 1. The Global Market for Pain Management Drugs and DevicesReport Details:Published:January 2013No. of Pages: 221Price: Single User License – US$5450REPORT HIGHLIGHTSThis report provides:•An overview of the global market for pain management drugs, which will address acute vs. chronic pain, treatments, and issues facing healthcare workers.•Analyses of global market trends, with data from 2012, and projections of compound annual growth rates (CAGRs) through 2017.•Examination of product categories, use of products, and the competitive landscape.•Coverage of several significant market trends, including undertreatment issues, professional issues, managed care pain issues, trends in new therapies, product pipelines, generic participation, pain research, drug delivery, and patent expirations.•Discussion of new regulatory requirements.•Comprehensive company profiles of major players in the industry.REPORT SCOPEINTRODUCTIONSTUDY GOALS AND OBJECTIVESThis BCC Research report, The Global Market for Pain Management Drugs and Devices, providesan overview of products included in this market, and detailed analyses of markets and competitiveenvironments. The study includes information about significant products, players, issues andtrends, regulatory issues, and other information affecting the pain management industry.REASONS FOR DOING THE STUDYThis study will provide the reader with the knowledge to adequately view and assess painmanagement and the problems that the healthcare industry faces as well as provide insights intothe market potentials. This covers a wide variety of treatments and products that many peopleworldwide rely on.SCOPE AND FORMATThis BCC Research report is designed to be a helpful business tool that will provide a thoroughevaluation of the markets for pain management. The geographical scope of this study is globalwith a U.S. emphasis. This study will address acute versus chronic pain, treatments, andregulatory issues facing healthcare workers. Also provided is detailed information based onproduct categories, use of products, forecasts, and competitive analyses.
  2. 2. The report identifies two general segments of pain management:•Pharmaceuticals.•Devices.Within the pharmaceuticals segment several sub-segments are discussed in detailincluding:•Narcotic pain management.•Non-narcotic pain management.•Antimigraine treatments.•Anesthetics.•Other drugs (including fibromyalgia treatments).The device segment covers several product lines and specifically targets the largestproduct segments including:•TENS and neuromuscular stimulators.•Spinal cord stimulators.•Other products (including electromagnetic therapies and other treatments).Each market segment provides detailed information based on product categories, product use,forecasts, and competitive analyses.METHODOLOGYThe information for this BCC report was obtained through primary and secondary data-collectionmethods. Primary methods included interviews with approximately 35 key executives, physicians,nurses, product managers, and other professionals involved in the pain treatment industry.Secondary methods included published literature in the area of pain management, investmentreports, company literature, and various related journals.Market data for this report pertains to the global market and uses U.S. dollars at themanufacturers’ level. The base year of the report is 2012, with historical data provided for 2008through 2011, and forecast data provided through 2017. Historical, base year and forecast dataare provided for each market segment of the report. Growth rates are determined through acompilation of data, including past trends, future trends, demographics, incidence, mortality,products in research and development, and current product growth, etc. Competitor market shareestimates are provided for each market segment for the 2012 base year.Get your copy of this report @http://www.reportsnreports.com/reports/213310-the-global-market-for-pain-management-drugs-and-devices.htmlMajor points covered in Table of Contents of this report includeTABLE OF CONTENTSChapter- 1: INTRODUCTIONSTUDY GOALS AND OBJECTIVESREASONS FOR DOING THE STUDYSCOPE AND FORMATMETHODOLOGYANALYST CREDENTIALS
  3. 3. RELATED BCC STUDIESBCC ON-LINE SERVICESDISCLAIMERChapter- 2: SUMMARYOVERVIEWGENERAL PAIN TERMINOLOGYMAJOR MARKETS SUMMARYMARKET TRENDSCOMPETITORSChapter- 3: INDUSTRY OVERVIEWHISTORY OF PAIN AND PAIN TREATMENTHOW PAIN IS DIAGNOSEDHOW PAIN IS TREATEDChapter- 4: INDUSTRY TRENDSOVERVIEWUNDERTREATMENT ISSUESTREATMENT OF PAIN AND ISSUES FACING THE PROFESSIONAL SEGMENTACCESS TO CAREPUBLIC HEALTHCARE SYSTEMS AROUND THE WORLDMANAGED CARE PAIN MANAGEMENT ISSUESFDA APPROVAL REQUIREMENTS FOR PAIN THERAPIESDRUG DELIVERY SYSTEMSChapter- 5: TREATING PAINPHARMACEUTICAL PAIN MANAGEMENTOVER-THE-COUNTER PAIN MANAGEMENT PRODUCTSPAIN MANAGEMENT DEVICESPAIN MANAGEMENT PROCEDURES: STEROIDS, ENDOSCOPY, FLUOROSCOPYALTERNATIVE METHODS OF PAIN MANAGEMENTPAIN MANAGEMENT SERVICES AND ORGANIZATIONSChapter- 6: PRESCRIPTION PAIN MANAGEMENT MARKET SIZE AND ANALYSISTOTAL MARKETPRESCRIPTION PAIN MARKETS BY PRODUCT TYPEMARKET PARTICIPANTSFUTURE MARKET ANALYSISChapter- 7: PAIN MANAGEMENT DEVICE MARKET SIZE AND ANALYSISTOTAL PAIN MANAGEMENT DEVICE MARKETPAIN MARKETS BY PRODUCT TYPEMARKET PARTICIPANTSFUTURE MARKET ANALYSISChapter- 8: TOTAL MARKET SUMMARYTOTAL PAIN MANAGEMENT MARKETMARKET PERCENTAGE BY PRODUCT TYPE
  4. 4. MARKETS BY WORLD REGIONChapter- 9: INDUSTRY DEVELOPMENTSTIMELINE OF RECENT EVENTS AND DEVELOPMENTSTHE PIPELINENEW DEVELOPMENTS IN BREAKTHROUGH CANCER PAINNEW DEVELOPMENTS IN TREATING NEUROPATHIC PAINDEVELOPMENTS IN OPIOID-INDUCED CONSTIPATION AND REDUCED COMPLIANCEFUTURE OF PAIN RESEARCHPATIENT OUTCOMES RESEARCHSELECTED PAIN-RELATED ACQUISITIONS AND ALLIANCESDRUG PATENTS FOR SELECTED THERAPIESChapter- 10: COMPANY PROFILESPHARMACEUTICAL AND DEVICE PAIN MANAGEMENT MANUFACTURERSABBOTT LABORATORIESASTRAZENECABAXTER INTERNATIONAL INC.DJO GLOBAL, INC.ELI LILLY & CO.ENDO PHARMACEUTICALS, INC.GLAXOSMITHKLINEJOHNSON & JOHNSONMEDTRONIC, INC.MERCK & CO. INC.NOVARTIS INTERNATIONAL AGPFIZERPURDUE PHARMACEUTICALS LPST. JUDE MEDICAL, INC.Chapter- 11: APPENDIX I: SELECTED PAIN MANAGEMENT CLINICS-UNITED STATES-BYSTATEALABAMA PAIN CLINICSCALIFORNIA PAIN CLINICSCOLORADO PAIN CLINICSDELAWARE PAIN CLINICSFLORIDA PAIN CLINICSHAWAII PAIN CLINICSIOWA PAIN CLINICSMAINE PAIN CLINICSNEVADA PAIN CLINICSOREGON PAIN CLINICSPENNSYLVANIA PAIN CLINICSRHODE ISLAND PAIN CLINICSSOUTH DAKOTA PAIN CLINICS
  5. 5. TEXAS PAIN CLINICSWASHINGTON PAIN CLINICSChapter- 12: APPENDIX II: GLOBAL SELECTED PAIN MANAGEMENT CLINICS, BYCOUNTRYARGENTINA PAIN CLINICSAUSTRALIA PAIN CLINICSBRAZIL PAIN CLINICSGERMANY PAIN CLINICSINDIA PAIN CLINICSITALY PAIN CLINICSSINGAPORE PAIN CLINICSUNITED KINGDOM PAIN CLINICSChapter- 13: APPENDIX III: U.S. PAIN SOCIETIES AND ASSOCIATIONSChapter- 14: APPENDIX IV: INTERNATIONAL ASSOCIATIONS AND ORGANIZATIONSChapter- 15: APPENDIX V: COMPANY NAMES AND ADDRESSESPAIN MANAGEMENT PHARMACEUTICAL MANUFACTURERSLIST OF TABLESSummary Table : GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICESMARKET, 2012 AND 2017Table 1 : OBJECTIVE SIGNS OF PAINTable 2 : ESTIMATED GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGEGROUP AND SELECTED YEARS, THROUGH 2030Table 3 : GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015Table 4 : GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010Table 5 : SEVERE HEADACHE OR MIGRAINE, LOW BACK PAIN, AND NECK PAIN AMONGADULTS 18 YEARS OF AGE AND OVER*, 2005-2009Table 6 : ESTIMATED* PREVALENCE/INCIDENCE OF CONDITIONS AFFECTING THEWORLDWIDE ORTHOPEDIC INDUSTRY, AVERAGE FIGURE, 2008-2010Table 7 : CANCER PAIN MEDICATIONTable 8 : ESTIMATED HIV REPORTED CASES BY REGION, 2011Table 9 : BURN CLASSIFICATIONSTable 10 : BIRTH RATES AND BIRTHS BY COUNTRY, 2010 ESTIMATESTable 11 : U.S. SURGICAL PROCEDURESTable 12 : SELECT SURGICAL PROCEDURES FOR GERMANY, UNITED KINGDOM, ANDFRANCETable 13 : PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION*Table 14 : AVAILABILITY OF EDUCATION IN PAIN MANAGEMENT BY SELECTREGION/COUNTRYTable 15 : TOTAL NUMBER OF ABUSE TREATMENT FACILITIES AND CLIENTS, 2000–2010Table 16 : BENEFITS OF PRESCRIPTION MONITORING PROGRAMS FOR MEDICAL BOARDSTable 17 : STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMSTable 18 : STATE CONTROLLED SUBSTANCES SCHEDULING AUTHORITIES AND OTHER
  6. 6. CONTACT INFORMATIONTable 19 : NURSE CONTINUING EDUCATION REQUIREMENTS FOR PAIN MANAGEMENT,BY REQUIRING STATETable 20 : PHYSICIANS PER 1,000 POPULATION BY YEAR AND COUNTRYTable 21 : NUMBER OF PHYSICIAN PER 100,000 RESIDENT POPULATION, UNITED STATES,2009Table 22 : AVAILABILITY OF INJECTABLE MORPHINE BY COUNTRYTable 23 : AVAILABILITY OF ORAL MORPHINE IN HOSPICE-TYPE SETTINGS BY COUNTRYTable 24 : WORLD HEALTH ORGANIZATION RANKING OF HEALTHCARE SYSTEMS, TOP 50(2000)Table 25 : HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY, 1980 TO 2010Table 26 : HOSPITAL USAGE STATISTICS, AVERAGE 2000-2010Table 27 : LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID PRODUCTSREQUIRED TO HAVE AN OPIOID REMS, BRAND NAME PRODUCTSTable 28 : LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID PRODUCTSREQUIRED TO HAVE AN OPIOID REMS, GENERIC NAME PRODUCTSTable 29 : LIST OF TRANSMUCOSAL IMMEDIATE-RELEASE FENTANYL PRODUCTSREQUIRED TO HAVE TIRF REMS ACCESS PROGRAMTable 30 : LIST OF MARKETED ACETAMINOPHEN-CONTAINING PRESCRIPTIONPRODUCTSTable 31 : ADVANTAGES OF IONTOPHORETIC DRUG DELIVERYTable 32 : RECENT FDA APPLICATIONS/APPROVALS, JANUARY 2010-OCTOBER 2012Table 33 : MOST COMMONLY USED GENERAL ANESTHETIC AGENTSTable 34 : ACETAMINOPHEN AND ACETAMINOPHEN COMBINATION PRODUCTSTable 35 : ASPIRIN AND ASPIRIN COMBINATION PRODUCTSTable 36 : IBUPROFEN AND IBUPROFEN COMBINATION PRODUCTSTable 37 : KETOPROFEN PRODUCTSTable 38 : OTC NONSTEROID ANTI-INFLAMMATORIESTable 39 : ANTI-MIGRAINE PRODUCTSTable 40 : TOPICAL ANESTHETIC PRODUCTSTable 41 : UNITED STATES: ADULTS 18 YEARS AND OVER WHO USED COMPLEMENTARYAND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY TYPE AND THERAPY,2002-2012Table 42 : HOSPICE STATISTICS, PATIENTS BY CHARACTERISTICS, 2009 AND 2010Table 43 : HOSPICE STATISTICS, PATIENTS BY PRIMARY DIAGNOSISTable 44 : NHPCO COMMITTEES AND TASK FORCESTable 45 : ESTIMATED NUMBER OF REGISTERED HOSPITALS BY SELECTED COUNTRY,2010 ESTIMATESTable 46 : TOTAL NUMBER OF REGISTERED U.S. HOSPITALS BY TYPE, 2010Table 47 : GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS MARKET ATMANUFACTURERS’ SALES LEVELS, THROUGH 2017Table 48 : PRESCRIPTION NARCOTIC AND NON-NARCOTIC MANUFACTURER MARKET
  7. 7. SHARE BY REVENUE, 2012Table 49 : PRESCRIPTION ANTI-MIGRAINE DRUG MANUFACTURER MARKET SHARE BYREVENUE, 2012Table 50 : PRESCRIPTION ANESTHETIC MANUFACTURER MARKET SHARE BY REVENUE,2012Table 51 : GLOBAL PAIN MANAGEMENT DEVICES MARKET BY PRODUCT TYPE, THROUGH2017Table 52 : GLOBAL NEUROMUSCULAR STIMULATOR/TENS—ELECTROTHERAPYDEVICES—MANUFACTURER MARKET SHARE, 2012Table 53 : GLOBAL SPINAL CORD STIMULATOR MANUFACTURER MARKET SHARE, 2012Table 54 : PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET BY REVENUE,THROUGH 2017Table 55 : PERCENT DISTRIBUTION OF THE GLOBAL PAIN MANAGEMENT MARKET BYSEGMENT, 2012Table 56 : DISTRIBUTION OF GLOBAL PAIN MANAGEMENT REVENUES BY REGION, 2012Table 57 : SELECTED PAIN-MANAGEMENT DRUG PIPELINESTable 58 : U.S. PATENT EXPIRATION DATES FOR SELECT PAIN DRUGSTable 59 : FIRST TIME PRESCRIPTION GENERIC PAIN MANAGEMENT AND APPROVALS,JANUARY 2004-OCTOBER 2012LIST OF FIGURESSummary Figure : GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICESMARKET, 2012 AND 2017Figure 1 : PAIN-MANAGEMENT TECHNIQUESFigure 2 : ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTEDYEARS, 2000-2030Figure 3 : GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND PROJECTED 2015Figure 4 : GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010Figure 5 : GLOBAL CANCER DEATHS BY TYPE, 2008Figure 6 : SEVERE HEADACHE OR MIGRAINE, LOW BACK PAIN, AND NECK PAIN AMONGADULTS 18 YEARS OF AGE AND OVER*, 2005-2009Figure 7 : ESTIMATED* PREVALENCE/INCIDENCE OF CONDITIONS AFFECTING THEWORLDWIDE ORTHOPEDIC INDUSTRY, AVERAGE FIGURE 2008–2010Figure 8 : CAUSES OF CANCER PAINFigure 9 : ADULT PREVALENCE RATE, 2011Figure 10 : BURN PAIN MANAGEMENT APPROACHFigure 11 : BIRTH RATES AND BIRTHS BY COUNTRY, 2010 ESTIMATESFigure 12 : PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION*Figure 13 : TOTAL NUMBER OF ABUSE TREATMENT FACILITIES, 2000–2010Figure 14 : TOTAL NUMBER OF ABUSE TREATMENT CLIENTS, 2000–2010Figure 15 : PHYSICIANS PER 1,000 POPULATION BY COUNTRY, 2010*Figure 16 : NUMBER OF PHYSICIANS PER 100,000 RESIDENT POPULATION, UNITEDSTATES 2009
  8. 8. Figure 17 : HOSPITAL USAGE STATISTICSFigure 18 : UNITED STATES: ADULTS 18 YEARS AND OVER WHO USED COMPLEMENTARYAND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY TYPE AND THERAPY,2002-2012Figure 19 : TOTAL HOSPICE PATIENTS SERVED BY YEAR, 2006-2010Figure 20 : TOTAL HOSPICE PATIENTS BY GENDER, 2009 AND 2010Figure 21 : TOTAL HOSPICE PATIENTS BY AGE, 2009 AND 2010Figure 22 : TOTAL HOSPICE PATIENTS BY PRIMARY DIAGNOSIS, 2009 AND 2010Figure 23 : GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS MARKET ATMANUFACTURERS’ SALES LEVELS, 2008-2017Figure 24 : PRESCRIPTION NARCOTIC AND NON-NARCOTIC MANUFACTURER MARKETSHARE BY REVENUE, 2012Figure 25 : PRESCRIPTION ANTI-MIGRAINE DRUG MANUFACTURER MARKET SHARE BYREVENUE, 2012Figure 26 : PRESCRIPTION ANESTHETIC MANUFACTURER MARKET SHARE BY REVENUE,2012Figure 27 : GLOBAL PAIN MANAGEMENT DEVICES MARKET BY PRODUCT TYPE, 2008-2017Figure 28 : GLOBAL NEUROMUSCULAR STIMULATOR/TENS—ELECTROTHERAPYDEVICES—MANUFACTURER MARKET SHARE, 2012Figure 29 : GLOBAL SPINAL CORD STIMULATOR MANUFACTURER MARKET SHARE, 2012Figure 30 : PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET BY REVENUE,2008-2017Figure 31 : PERCENT DISTRIBUTION OF THE GLOBAL PAIN MANAGEMENT MARKET BYSEGMENT, 2012Figure 32 : PERCENTAGE DISTRIBUTION OF GLOBAL PAIN MANAGEMENT SHARES BYREGION, 2012Contact: sales@reportsandreports.com for more information.

×